Use of the ActiMyo Sensor to Assess 95th Centile of Stride Velocity: Laurent Servais, MD, PhD

WATCH TIME: 4 minutes

“My patients can sometimes be motivated and sometimes not. My patients can be willing to perform because he wants to enter the study or not. So you can imagine that there are plenty of factors that affect the reliability of whatever we measure."

Assessing investigational therapies for patients with Duchenne muscular dystrophy (DMD) in a reasonable timeframe can be challenging because of lack of objective, reliable, and sensitive outcome measures. In addition, sporadic, clinic-based motor function testing can provide a snapshot of a patients’ condition at the time of testing and may be compromised by factors including the patient’s motivation or level of fatigue. This is especially true for patients less than 5 years old who can be poorly compliant with standardized assessments.

At the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, held March 3-6, in Orlando, Florida, researchers presented data from a longitudinal multicentric study validating 95th centile of stride velocity (SV95C) as a reliable outcome measure. In 2019, SV95C became the first wearable-derived digital clinical outcome assessment qualified by the European Medicines Agency for use as a secondary end point in trials for DMD. For context, SV95C is an objective, real-world digital ambulation measure of peak performance, representing the speed of the fastest strides taken by the wearer over a recording period of 180 hours.

Also known as the ActiLiege-Next study, this 3-year trial assessed the use of a wearable, fit-for-purpose, magneto-inertial sensor, ActiMyo/Syde, in ambulant patients with DMD and healthy controls aged 2-15 years old. Preliminary analyses in those aged at least 5 years old showed excellent SV95C reliability, with an age-independent intra-class correlation of 0.97. The Pearson correlation with North Star Ambulatory Assessment, 6-Minute Walk Test, and 4-stair climbing test was 0.71, 0.59, and –0.73, respectively (n = 65-67).

Servais, a professor of pediatric neuromuscular diseases at the University of Oxford, sat down with NeurologyLive® at the conference to discuss the ActiMyo device and how it can be used to capture SV95C. He spoke on the fundamental aspects of the sensor, its use in real-world settings, and the advantages it brings. In addition, he provided insight on the clinical utility of SV95C and when it could become more widely used in clinical trial settings.

Click here for more coverage of MDA 2024.

REFERENCE
1. Servais L, Parinello G, Poleur M, et al. Longitudinal multicentric study to validate SV95C in ambulant DMD aged 2-15 years old. Presented at: MDA Clinical and Scientific Conference; March 3-6, 2024; Orlando, FL. M169